Trial Profile
Study of the safety and efficacy of daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TDF2
- 16 Dec 2015 Results of sub-group analysis (n=4) published in the JAIDS
- 11 Jul 2012 Results published in the New England Journal of Medicine.
- 21 Jun 2012 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.